3 - 6 महीने के लिए सर्वश्रेष्ठ म्युचुअल फंड

Updated on July 29, 2026 , 112301 views

3 से 6 महीने की छोटी अवधि के लिए, आप या तो अपना पैसा इसमें लगा सकते हैंतरल म्युचुअल फंड या अल्ट्रा शॉर्ट टर्मडेट म्यूचुअल फंड. तरलम्यूचुअल फंड्स आमतौर पर सरकारी प्रतिभूतियों और 3 महीने तक की अवधि के जमा प्रमाणपत्र में निवेश करते हैं।

हालांकि, अगर कोई उच्च रिटर्न के लिए जोखिम लेने के लिए उत्सुक है तो नीचे कुछ विकल्प देख सकते हैं

शीर्ष 5 हॉट म्युचुअल फंड 3 महीने

नीचे की सूची हैसर्वश्रेष्ठ म्युचुअल फंड शुद्ध संपत्ति खत्म होना100 करोड़ और पिछले 3 महीनों में सबसे अच्छा रिटर्न दिया है।

1. SBI Healthcare Opportunities Fund

(Erstwhile SBI Pharma Fund)

To provide the investors maximum growth opportunity through equity investments in stocks of growth oriented sectors of the economy.

Research Highlights for SBI Healthcare Opportunities Fund

Upper mid AUM (₹4,998 Cr).
Established history (21+ yrs).
Rating: 2★ (lower mid).
Risk profile: High.
5Y return: 16.97% (top quartile).
3Y return: 23.13% (upper mid).
1Y return: 16.28% (upper mid).
Alpha: 2.23 (upper mid).
Sharpe: 0.59 (top quartile).
Information ratio: -0.17 (upper mid).
Top sector: Health Care.
Top bond sector: Cash Equivalent.
Equity-heavy allocation (~97%).
High-quality debt (AAA/AA ~100%).
Largest holding Sun Pharmaceuticals Industries Ltd (~11.0%).

Below is the key information for SBI Healthcare Opportunities Fund

SBI Healthcare Opportunities Fund Growth
Launch Date	31 Dec 04
NAV (31 Jul 26)	₹513.305 ↑ 1.98 (0.39 %)
Net Assets (Cr)	₹4,998 on 30 Jun 26
Category	Equity - Sectoral
AMC	SBI Funds Management Private Limited
Rating	☆☆
Risk	High
Expense Ratio	1.97
Sharpe Ratio	0.59
Information Ratio	-0.17
Alpha Ratio	2.23
Min Investment	5,000
Min SIP Investment	500
Exit Load	0-15 Days (0.5%),15 Days and above(NIL)

Growth of 10,000 investment over the years.

Date	Value
31 Jul 21	₹10,000
31 Jul 22	₹8,982
31 Jul 23	₹11,731
31 Jul 24	₹16,334
31 Jul 25	₹18,834

SBI Healthcare Opportunities Fund SIP Returns

Total investment amount is ₹300,000
expected amount after 5 Years is ₹458,689.
Net Profit of ₹158,689 Invest Now

Returns for SBI Healthcare Opportunities Fund

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 31 Jul 26

Duration	Returns
1 Month	4.1%
3 Month	16.9%
6 Month	26.5%
1 Year	16.3%
3 Year	23.1%
5 Year	17%
10 Year
15 Year
Since launch	15.7%

Historical performance (Yearly) on absolute basis

Year	Returns
2024	-3.5%
2023	42.2%
2022	38.2%
2021	-6%
2020	20.1%
2019	65.8%
2018	-0.5%
2017	-9.9%
2016	2.1%
2015	-14%

Fund Manager information for SBI Healthcare Opportunities Fund

Name	Since	Tenure
Tanmaya Desai	1 Jun 11	15.09 Yr.

Data below for SBI Healthcare Opportunities Fund as on 30 Jun 26

Equity Sector Allocation

Sector	Value
Health Care	88.67%
Basic Materials	8.82%

Asset Allocation

Asset Class	Value
Cash	2.45%
Equity	97.49%
Debt	0.06%

Top Securities Holdings / Portfolio

Name	Holding	Value	Quantity
Sun Pharmaceuticals Industries Ltd (Healthcare) Equity, Since 31 Dec 17 \| SUNPHARMA	11%	₹504 Cr	2,800,000
Divi's Laboratories Ltd (Healthcare) Equity, Since 31 Mar 12 \| DIVISLAB	7%	₹300 Cr	450,000
Acutaas Chemicals Ltd (Basic Materials) Equity, Since 30 Jun 24 \| 543349	6%	₹282 Cr	900,000
Apollo Hospitals Enterprise Ltd (Healthcare) Equity, Since 31 Jan 26 \| APOLLOHOSP	5%	₹245 Cr	300,000
Max Healthcare Institute Ltd Ordinary Shares (Healthcare) Equity, Since 31 Mar 21 \| MAXHEALTH	5%	₹217 Cr	2,250,000
Aurobindo Pharma Ltd (Healthcare) Equity, Since 31 Mar 26 \| AUROPHARMA	4%	₹178 Cr	1,250,000 ↑ 250,000
Aster DM Healthcare Ltd Ordinary Shares (Healthcare) Equity, Since 31 Mar 24 \| ASTERDM	4%	₹175 Cr	2,400,000
Laurus Labs Ltd (Healthcare) Equity, Since 31 Aug 23 \| LAURUSLABS	4%	₹163 Cr	1,200,000
Biocon Ltd (Healthcare) Equity, Since 30 Nov 24 \| BIOCON	4%	₹161 Cr	3,750,000
Torrent Pharmaceuticals Ltd (Healthcare) Equity, Since 30 Jun 21 \| TORNTPHARM	3%	₹159 Cr	360,000

2. UTI Healthcare Fund

(Erstwhile UTI Pharma & Healthcare Fund)

The Investment objective of the Scheme is capital appreciation through investments in equities and equity related instruments of the Pharma & Healthcare sectors.

Research Highlights for UTI Healthcare Fund

Bottom quartile AUM (₹1,308 Cr).
Established history (27+ yrs).
Rating: 1★ (bottom quartile).
Risk profile: High.
5Y return: 14.70% (upper mid).
3Y return: 23.21% (top quartile).
1Y return: 12.75% (lower mid).
Alpha: 2.15 (lower mid).
Sharpe: 0.58 (upper mid).
Information ratio: 0.20 (top quartile).
Higher exposure to Health Care vs peer median.
Top bond sector: Cash Equivalent.
Equity-heavy allocation (~94%).
Largest holding Sun Pharmaceuticals Industries Ltd (~8.9%).

Below is the key information for UTI Healthcare Fund

UTI Healthcare Fund Growth
Launch Date	28 Jun 99
NAV (31 Jul 26)	₹334.51 ↑ 0.45 (0.14 %)
Net Assets (Cr)	₹1,308 on 30 Jun 26
Category	Equity - Sectoral
AMC	UTI Asset Management Company Ltd
Rating	☆
Risk	High
Expense Ratio	2.26
Sharpe Ratio	0.58
Information Ratio	0.2
Alpha Ratio	2.15
Min Investment	5,000
Min SIP Investment	500
Exit Load	0-1 Years (1%),1 Years and above(NIL)

Growth of 10,000 investment over the years.

Date	Value
31 Jul 21	₹10,000
31 Jul 22	₹8,749
31 Jul 23	₹10,615
31 Jul 24	₹15,542
31 Jul 25	₹17,610

UTI Healthcare Fund SIP Returns

Total investment amount is ₹300,000
expected amount after 5 Years is ₹436,710.
Net Profit of ₹136,710 Invest Now

Returns for UTI Healthcare Fund

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 31 Jul 26

Duration	Returns
1 Month	2.6%
3 Month	14.3%
6 Month	22.9%
1 Year	12.7%
3 Year	23.2%
5 Year	14.7%
10 Year
15 Year
Since launch	15%

Historical performance (Yearly) on absolute basis

Year	Returns
2024	-3.1%
2023	42.9%
2022	38.2%
2021	-12.3%
2020	19.1%
2019	67.4%
2018	1.2%
2017	-7.5%
2016	6.2%
2015	-9.7%

Fund Manager information for UTI Healthcare Fund

Name	Since	Tenure
Kamal Gada	2 May 22	4.17 Yr.

Data below for UTI Healthcare Fund as on 30 Jun 26

Equity Sector Allocation

Sector	Value
Health Care	94.45%

Asset Allocation

Asset Class	Value
Cash	5.55%
Equity	94.45%

Top Securities Holdings / Portfolio

Name	Holding	Value	Quantity
Sun Pharmaceuticals Industries Ltd (Healthcare) Equity, Since 31 Oct 06 \| SUNPHARMA	9%	₹108 Cr	600,000
Divi's Laboratories Ltd (Healthcare) Equity, Since 30 Sep 17 \| DIVISLAB	5%	₹59 Cr	88,814 ↑ 28,076
Ajanta Pharma Ltd (Healthcare) Equity, Since 31 Jul 17 \| AJANTPHARM	5%	₹57 Cr	195,295 ↓ -41,216
Gland Pharma Ltd (Healthcare) Equity, Since 30 Nov 20 \| GLAND	4%	₹48 Cr	215,251
Lupin Ltd (Healthcare) Equity, Since 28 Feb 25 \| LUPIN	4%	₹46 Cr	203,834 ↓ -6,166
Apollo Hospitals Enterprise Ltd (Healthcare) Equity, Since 30 Apr 21 \| APOLLOHOSP	4%	₹43 Cr	53,000
Dr Reddy's Laboratories Ltd (Healthcare) Equity, Since 28 Feb 18 \| DRREDDY	3%	₹38 Cr	290,000
Caplin Point Laboratories Ltd (Healthcare) Equity, Since 31 Dec 23 \| CAPLIPOINT	3%	₹37 Cr	185,000 ↑ 39,847
Alkem Laboratories Ltd (Healthcare) Equity, Since 31 May 21 \| ALKEM	3%	₹37 Cr	68,000
Fortis Healthcare Ltd (Healthcare) Equity, Since 31 Dec 20 \| FORTIS	3%	₹37 Cr	400,000

3. Motilal Oswal Focused 25 Fund

(Erstwhile Motilal Oswal MOSt Focused 25 Fund)

The investment objective of the Scheme is to achieve long term capital appreciation by investing in upto 25 companies with long term sustainable competitive advantage and growth potential. However, there can be no assurance or guarantee that the investment objective of the Scheme would be achieved.

Research Highlights for Motilal Oswal Focused 25 Fund

Lower mid AUM (₹1,635 Cr).
Established history (13+ yrs).
Top rated.
Risk profile: Moderately High.
5Y return: 9.85% (bottom quartile).
3Y return: 11.56% (bottom quartile).
1Y return: 16.56% (top quartile).
Alpha: 12.39 (top quartile).
Sharpe: 0.35 (lower mid).
Information ratio: -0.21 (lower mid).
Top sector: Financial Services.
Top bond sector: Cash Equivalent.
Equity-heavy allocation (~94%).
Largest holding Aditya Infotech Ltd (~4.9%).

Below is the key information for Motilal Oswal Focused 25 Fund

Motilal Oswal Focused 25 Fund Growth
Launch Date	7 May 13
NAV (31 Jul 26)	₹50.3259 ↑ 0.64 (1.29 %)
Net Assets (Cr)	₹1,635 on 30 Jun 26
Category	Equity - Focused
AMC	Motilal Oswal Asset Management Co. Ltd
Rating	☆☆☆
Risk	Moderately High
Expense Ratio	1.97
Sharpe Ratio	0.35
Information Ratio	-0.21
Alpha Ratio	12.39
Min Investment	5,000
Min SIP Investment	500
Exit Load	0-1 Years (1%),1 Years and above(NIL)

Growth of 10,000 investment over the years.

Date	Value
31 Jul 21	₹10,000
31 Jul 22	₹10,120
31 Jul 23	₹11,523
31 Jul 24	₹15,422
31 Jul 25	₹13,725

Motilal Oswal Focused 25 Fund SIP Returns

Total investment amount is ₹300,000
expected amount after 5 Years is ₹385,859.
Net Profit of ₹85,859 Invest Now

Returns for Motilal Oswal Focused 25 Fund

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 31 Jul 26

Duration	Returns
1 Month	3.4%
3 Month	12.4%
6 Month	18.6%
1 Year	16.6%
3 Year	11.6%
5 Year	9.9%
10 Year
15 Year
Since launch	13%

Historical performance (Yearly) on absolute basis

Year	Returns
2024	-1.7%
2023	13.6%
2022	18.8%
2021	2%
2020	14.6%
2019	17.3%
2018	17.1%
2017	-4.2%
2016	32.2%
2015	2.8%

Fund Manager information for Motilal Oswal Focused 25 Fund

Name	Since	Tenure
Varun Sharma	14 Aug 25	0.88 Yr.
Swapnil Mayekar	18 Nov 25	0.61 Yr.
Ankit Agarwal	5 Aug 25	0.9 Yr.
Rakesh Shetty	22 Nov 22	3.61 Yr.
Atul Mehra	1 Oct 24	1.75 Yr.

Data below for Motilal Oswal Focused 25 Fund as on 30 Jun 26

Equity Sector Allocation

Sector	Value
Financial Services	23.84%
Industrials	21.59%
Consumer Cyclical	17.2%
Technology	8.99%
Health Care	7.23%
Basic Materials	7.03%
Utility	3.18%
Communication Services	2.46%

Asset Allocation

Asset Class	Value
Cash	5.55%
Equity	94.45%

Top Securities Holdings / Portfolio

Name	Holding	Value	Quantity
Aditya Infotech Ltd (Industrials) Equity, Since 28 Feb 26 \| CPPLUS	5%	₹76 Cr	261,175
ICICI Prudential Asset Management Co Ltd (Financial Services) Equity, Since 31 Jan 26 \| ICICIAMC	4%	₹68 Cr	193,190 ↑ 8,826
Persistent Systems Ltd (Technology) Equity, Since 30 Apr 26 \| PERSISTENT	4%	₹66 Cr	127,008 ↑ 19,051
CG Power & Industrial Solutions Ltd (Industrials) Equity, Since 28 Feb 26 \| CGPOWER	4%	₹65 Cr	707,583 ↓ -71,782
AU Small Finance Bank Ltd (Financial Services) Equity, Since 31 Oct 25 \| AUBANK	4%	₹64 Cr	645,708 ↑ 40,286
Eternal Ltd (Consumer Cyclical) Equity, Since 31 Jan 26 \| ETERNAL	4%	₹63 Cr	2,529,956 ↑ 118,365
Apollo Hospitals Enterprise Ltd (Healthcare) Equity, Since 28 Feb 26 \| APOLLOHOSP	4%	₹62 Cr	75,565 ↑ 4,721
Gabriel India Ltd (Consumer Cyclical) Equity, Since 31 Aug 25 \| GABRIEL	4%	₹59 Cr	536,227
Aditya Vision Ltd (Consumer Cyclical) Equity, Since 30 Sep 25 \| 540205	4%	₹55 Cr	1,020,017
ABB India Ltd (Industrials) Equity, Since 31 May 26 \| ABB	3%	₹54 Cr	74,566 ↑ 74,566

4. TATA India Pharma & Healthcare Fund

The investment objective of the scheme is to seek long term capital appreciation by investing atleast 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved.The Scheme does not assure or guarantee any returns.

Research Highlights for TATA India Pharma & Healthcare Fund

Bottom quartile AUM (₹1,455 Cr).
Established history (10+ yrs).
Not Rated.
Risk profile: High.
5Y return: 13.71% (lower mid).
3Y return: 19.41% (lower mid).
1Y return: 7.96% (bottom quartile).
Alpha: -7.90 (bottom quartile).
Sharpe: 0.16 (bottom quartile).
Information ratio: -0.61 (bottom quartile).
Top sector: Health Care.
Top bond sector: Cash Equivalent.
Equity-heavy allocation (~99%).
Largest holding Sun Pharmaceuticals Industries Ltd (~9.4%).

Below is the key information for TATA India Pharma & Healthcare Fund

TATA India Pharma & Healthcare Fund Growth
Launch Date	28 Dec 15
NAV (31 Jul 26)	₹33.7044 ↑ 0.03 (0.08 %)
Net Assets (Cr)	₹1,455 on 30 Jun 26
Category	Equity - Sectoral
AMC	Tata Asset Management Limited
Rating	Not Rated
Risk	High
Expense Ratio	2.17
Sharpe Ratio	0.16
Information Ratio	-0.61
Alpha Ratio	-7.9
Min Investment	5,000
Min SIP Investment	150
Exit Load	0-3 Months (0.25%),3 Months and above(NIL)

Growth of 10,000 investment over the years.

Date	Value
31 Jul 21	₹10,000
31 Jul 22	₹9,207
31 Jul 23	₹11,165
31 Jul 24	₹16,308
31 Jul 25	₹17,610

TATA India Pharma & Healthcare Fund SIP Returns

Total investment amount is ₹300,000
expected amount after 5 Years is ₹426,080.
Net Profit of ₹126,080 Invest Now

Returns for TATA India Pharma & Healthcare Fund

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 31 Jul 26

Duration	Returns
1 Month	4.2%
3 Month	12.2%
6 Month	18.1%
1 Year	8%
3 Year	19.4%
5 Year	13.7%
10 Year
15 Year
Since launch	12.2%

Historical performance (Yearly) on absolute basis

Year	Returns
2024	-4.9%
2023	40.4%
2022	36.6%
2021	-8%
2020	19.1%
2019	64.4%
2018	5.5%
2017	-2.6%
2016	4.7%
2015	-14.7%

Fund Manager information for TATA India Pharma & Healthcare Fund

Name	Since	Tenure
Rajat Srivastava	16 Sep 24	1.79 Yr.

Data below for TATA India Pharma & Healthcare Fund as on 30 Jun 26

Equity Sector Allocation

Sector	Value
Health Care	93.6%
Basic Materials	3.96%
Consumer Defensive	1.35%
Financial Services	0.4%

Asset Allocation

Asset Class	Value
Cash	0.7%
Equity	99.3%

Top Securities Holdings / Portfolio

Name	Holding	Value	Quantity
Sun Pharmaceuticals Industries Ltd (Healthcare) Equity, Since 31 Jan 16 \| SUNPHARMA	9%	₹130 Cr	723,130
HealthCare Global Enterprises Ltd (Healthcare) Equity, Since 31 Dec 18 \| HCG	6%	₹81 Cr	1,276,727 ↑ 15,000
Divi's Laboratories Ltd (Healthcare) Equity, Since 30 Sep 17 \| DIVISLAB	6%	₹80 Cr	120,600
Abbott India Ltd (Healthcare) Equity, Since 30 Sep 25 \| ABBOTINDIA	5%	₹75 Cr	27,953
Cipla Ltd (Healthcare) Equity, Since 30 Apr 20 \| CIPLA	5%	₹72 Cr	512,754
Max Healthcare Institute Ltd Ordinary Shares (Healthcare) Equity, Since 31 Jul 25 \| MAXHEALTH	5%	₹67 Cr	690,488
Apollo Hospitals Enterprise Ltd (Healthcare) Equity, Since 31 Dec 16 \| APOLLOHOSP	5%	₹63 Cr	77,345 ↑ 6,861
Rainbow Childrens Medicare Ltd (Healthcare) Equity, Since 31 Jul 25 \| 543524	5%	₹63 Cr	454,338 ↑ 7,205
Dr Reddy's Laboratories Ltd (Healthcare) Equity, Since 31 Aug 18 \| DRREDDY	4%	₹56 Cr	428,116 ↑ 54,652
Mankind Pharma Ltd (Healthcare) Equity, Since 30 Apr 23 \| MANKIND	4%	₹52 Cr	220,018

5. UTI Equity Fund

This Scheme primarily aims at securing for the unitholders capital appreciation by investing the funds of the scheme in equity shares and convertible and non-convertible bonds/ debentures of companies with good growth prospects and money market instruments.

Research Highlights for UTI Equity Fund

Highest AUM (₹22,882 Cr).
Oldest track record among peers (34 yrs).
Rating: 3★ (upper mid).
Risk profile: Moderately High.
5Y return: 6.36% (bottom quartile).
3Y return: 9.03% (bottom quartile).
1Y return: 1.25% (bottom quartile).
Alpha: -6.34 (bottom quartile).
Sharpe: -0.69 (bottom quartile).
Information ratio: -0.98 (bottom quartile).
Top sector: Financial Services.
Top bond sector: Cash Equivalent.
Equity-heavy allocation (~97%).
High-quality debt (AAA/AA ~100%).
Largest holding Bajaj Finance Ltd (~6.3%).

Below is the key information for UTI Equity Fund

UTI Equity Fund Growth
Launch Date	18 May 92
NAV (31 Jul 26)	₹327.664 ↑ 1.63 (0.50 %)
Net Assets (Cr)	₹22,882 on 30 Jun 26
Category	Equity - Multi Cap
AMC	UTI Asset Management Company Ltd
Rating	☆☆☆
Risk	Moderately High
Expense Ratio	1.66
Sharpe Ratio	-0.7
Information Ratio	-0.98
Alpha Ratio	-6.34
Min Investment	5,000
Min SIP Investment	500
Exit Load	0-1 Years (1%),1 Years and above(NIL)

Growth of 10,000 investment over the years.

Date	Value
31 Jul 21	₹10,000
31 Jul 22	₹9,828
31 Jul 23	₹10,501
31 Jul 24	₹13,048
31 Jul 25	₹13,441

UTI Equity Fund SIP Returns

Total investment amount is ₹300,000
expected amount after 5 Years is ₹357,992.
Net Profit of ₹57,992 Invest Now

Returns for UTI Equity Fund

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 31 Jul 26

Duration	Returns
1 Month	6.6%
3 Month	12%
6 Month	7.2%
1 Year	1.3%
3 Year	9%
5 Year	6.4%
10 Year
15 Year
Since launch	12.7%

Historical performance (Yearly) on absolute basis

Year	Returns
2024	1.1%
2023	14.3%
2022	19.8%
2021	-13.4%
2020	34%
2019	31.5%
2018	11.7%
2017	3.5%
2016	30.1%
2015	1.1%

Fund Manager information for UTI Equity Fund

Name	Since	Tenure
Ajay Tyagi	11 Jan 16	10.47 Yr.
Kamal Gada	8 Apr 25	1.23 Yr.
Akash Shah	12 Jan 26	0.46 Yr.

Data below for UTI Equity Fund as on 30 Jun 26

Equity Sector Allocation

Sector	Value
Financial Services	23.79%
Consumer Cyclical	22.82%
Health Care	12.37%
Technology	11.16%
Communication Services	7.92%
Industrials	7.41%
Consumer Defensive	5.84%
Basic Materials	5.68%

Asset Allocation

Asset Class	Value
Cash	2.79%
Equity	96.98%
Debt	0.22%

Top Securities Holdings / Portfolio

Name	Holding	Value	Quantity
Bajaj Finance Ltd (Financial Services) Equity, Since 30 Nov 17 \| 500034	6%	₹1,432 Cr	14,251,000 ↓ -755,500
ICICI Bank Ltd (Financial Services) Equity, Since 31 Oct 21 \| ICICIBANK	6%	₹1,428 Cr	10,384,000 ↓ -552,000
Eternal Ltd (Consumer Cyclical) Equity, Since 31 Jul 21 \| ETERNAL	6%	₹1,357 Cr	51,295,000 ↑ 643,300
HDFC Bank Ltd (Financial Services) Equity, Since 31 May 07 \| HDFCBANK	5%	₹1,219 Cr	15,273,000 ↓ -208,600
Titan Co Ltd (Consumer Cyclical) Equity, Since 31 Jul 11 \| TITAN	4%	₹926 Cr	2,102,200 ↓ -21,000
Avenue Supermarts Ltd (Consumer Defensive) Equity, Since 31 Jul 19 \| 540376	4%	₹831 Cr	1,896,750 ↓ -12,250
Bharti Airtel Ltd (Communication Services) Equity, Since 31 Jan 20 \| BHARTIARTL	3%	₹788 Cr	4,256,000 ↑ 73,700
Kotak Mahindra Bank Ltd (Financial Services) Equity, Since 30 Apr 15 \| KOTAKBANK	3%	₹772 Cr	19,690,000 ↓ -1,096,000
Coforge Ltd (Technology) Equity, Since 31 Jul 21 \| COFORGE	3%	₹755 Cr	5,148,500 ↓ -181,500
Dixon Technologies (India) Ltd (Technology) Equity, Since 31 Aug 23 \| DIXON	3%	₹705 Cr	591,400 ↓ -17,590

शीर्ष 5 हॉट म्युचुअल फंड 6 महीने

निवल संपत्ति से अधिक वाले सर्वश्रेष्ठ म्यूचुअल फंड की सूची नीचे दी गई है100 करोड़ और पिछले 6 महीनों में सबसे अच्छा रिटर्न दिया है।

1. SBI Healthcare Opportunities Fund

(Erstwhile SBI Pharma Fund)

To provide the investors maximum growth opportunity through equity investments in stocks of growth oriented sectors of the economy.

Research Highlights for SBI Healthcare Opportunities Fund

Highest AUM (₹4,998 Cr).
Established history (21+ yrs).
Rating: 2★ (upper mid).
Risk profile: High.
5Y return: 16.97% (upper mid).
3Y return: 23.13% (upper mid).
1Y return: 16.28% (lower mid).
Alpha: 2.23 (lower mid).
Sharpe: 0.59 (top quartile).
Information ratio: -0.17 (lower mid).
Higher exposure to Health Care vs peer median.
Top bond sector: Cash Equivalent.
Equity-heavy allocation (~97%).
High-quality debt (AAA/AA ~100%).
Largest holding Sun Pharmaceuticals Industries Ltd (~11.0%).

Below is the key information for SBI Healthcare Opportunities Fund

SBI Healthcare Opportunities Fund Growth
Launch Date	31 Dec 04
NAV (31 Jul 26)	₹513.305 ↑ 1.98 (0.39 %)
Net Assets (Cr)	₹4,998 on 30 Jun 26
Category	Equity - Sectoral
AMC	SBI Funds Management Private Limited
Rating	☆☆
Risk	High
Expense Ratio	1.97
Sharpe Ratio	0.59
Information Ratio	-0.17
Alpha Ratio	2.23
Min Investment	5,000
Min SIP Investment	500
Exit Load	0-15 Days (0.5%),15 Days and above(NIL)

Growth of 10,000 investment over the years.

Date	Value
31 Jul 21	₹10,000
31 Jul 22	₹8,982
31 Jul 23	₹11,731
31 Jul 24	₹16,334
31 Jul 25	₹18,834

SBI Healthcare Opportunities Fund SIP Returns

Total investment amount is ₹300,000
expected amount after 5 Years is ₹458,689.
Net Profit of ₹158,689 Invest Now

Returns for SBI Healthcare Opportunities Fund

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 31 Jul 26

Duration	Returns
1 Month	4.1%
3 Month	16.9%
6 Month	26.5%
1 Year	16.3%
3 Year	23.1%
5 Year	17%
10 Year
15 Year
Since launch	15.7%

Historical performance (Yearly) on absolute basis

Year	Returns
2024	-3.5%
2023	42.2%
2022	38.2%
2021	-6%
2020	20.1%
2019	65.8%
2018	-0.5%
2017	-9.9%
2016	2.1%
2015	-14%

Fund Manager information for SBI Healthcare Opportunities Fund

Name	Since	Tenure
Tanmaya Desai	1 Jun 11	15.09 Yr.

Data below for SBI Healthcare Opportunities Fund as on 30 Jun 26

Equity Sector Allocation

Sector	Value
Health Care	88.67%
Basic Materials	8.82%

Asset Allocation

Asset Class	Value
Cash	2.45%
Equity	97.49%
Debt	0.06%

Top Securities Holdings / Portfolio

Name	Holding	Value	Quantity
Sun Pharmaceuticals Industries Ltd (Healthcare) Equity, Since 31 Dec 17 \| SUNPHARMA	11%	₹504 Cr	2,800,000
Divi's Laboratories Ltd (Healthcare) Equity, Since 31 Mar 12 \| DIVISLAB	7%	₹300 Cr	450,000
Acutaas Chemicals Ltd (Basic Materials) Equity, Since 30 Jun 24 \| 543349	6%	₹282 Cr	900,000
Apollo Hospitals Enterprise Ltd (Healthcare) Equity, Since 31 Jan 26 \| APOLLOHOSP	5%	₹245 Cr	300,000
Max Healthcare Institute Ltd Ordinary Shares (Healthcare) Equity, Since 31 Mar 21 \| MAXHEALTH	5%	₹217 Cr	2,250,000
Aurobindo Pharma Ltd (Healthcare) Equity, Since 31 Mar 26 \| AUROPHARMA	4%	₹178 Cr	1,250,000 ↑ 250,000
Aster DM Healthcare Ltd Ordinary Shares (Healthcare) Equity, Since 31 Mar 24 \| ASTERDM	4%	₹175 Cr	2,400,000
Laurus Labs Ltd (Healthcare) Equity, Since 31 Aug 23 \| LAURUSLABS	4%	₹163 Cr	1,200,000
Biocon Ltd (Healthcare) Equity, Since 30 Nov 24 \| BIOCON	4%	₹161 Cr	3,750,000
Torrent Pharmaceuticals Ltd (Healthcare) Equity, Since 30 Jun 21 \| TORNTPHARM	3%	₹159 Cr	360,000

2. UTI Healthcare Fund

(Erstwhile UTI Pharma & Healthcare Fund)

The Investment objective of the Scheme is capital appreciation through investments in equities and equity related instruments of the Pharma & Healthcare sectors.

Research Highlights for UTI Healthcare Fund

Lower mid AUM (₹1,308 Cr).
Oldest track record among peers (27 yrs).
Rating: 1★ (lower mid).
Risk profile: High.
5Y return: 14.70% (lower mid).
3Y return: 23.21% (top quartile).
1Y return: 12.75% (bottom quartile).
Alpha: 2.15 (bottom quartile).
Sharpe: 0.58 (upper mid).
Information ratio: 0.20 (top quartile).
Higher exposure to Health Care vs peer median.
Top bond sector: Cash Equivalent.
Equity-heavy allocation (~94%).
Largest holding Sun Pharmaceuticals Industries Ltd (~8.9%).

Below is the key information for UTI Healthcare Fund

UTI Healthcare Fund Growth
Launch Date	28 Jun 99
NAV (31 Jul 26)	₹334.51 ↑ 0.45 (0.14 %)
Net Assets (Cr)	₹1,308 on 30 Jun 26
Category	Equity - Sectoral
AMC	UTI Asset Management Company Ltd
Rating	☆
Risk	High
Expense Ratio	2.26
Sharpe Ratio	0.58
Information Ratio	0.2
Alpha Ratio	2.15
Min Investment	5,000
Min SIP Investment	500
Exit Load	0-1 Years (1%),1 Years and above(NIL)

Growth of 10,000 investment over the years.

Date	Value
31 Jul 21	₹10,000
31 Jul 22	₹8,749
31 Jul 23	₹10,615
31 Jul 24	₹15,542
31 Jul 25	₹17,610

UTI Healthcare Fund SIP Returns

Total investment amount is ₹300,000
expected amount after 5 Years is ₹436,710.
Net Profit of ₹136,710 Invest Now

Returns for UTI Healthcare Fund

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 31 Jul 26

Duration	Returns
1 Month	2.6%
3 Month	14.3%
6 Month	22.9%
1 Year	12.7%
3 Year	23.2%
5 Year	14.7%
10 Year
15 Year
Since launch	15%

Historical performance (Yearly) on absolute basis

Year	Returns
2024	-3.1%
2023	42.9%
2022	38.2%
2021	-12.3%
2020	19.1%
2019	67.4%
2018	1.2%
2017	-7.5%
2016	6.2%
2015	-9.7%

Fund Manager information for UTI Healthcare Fund

Name	Since	Tenure
Kamal Gada	2 May 22	4.17 Yr.

Data below for UTI Healthcare Fund as on 30 Jun 26

Equity Sector Allocation

Sector	Value
Health Care	94.45%

Asset Allocation

Asset Class	Value
Cash	5.55%
Equity	94.45%

Top Securities Holdings / Portfolio

Name	Holding	Value	Quantity
Sun Pharmaceuticals Industries Ltd (Healthcare) Equity, Since 31 Oct 06 \| SUNPHARMA	9%	₹108 Cr	600,000
Divi's Laboratories Ltd (Healthcare) Equity, Since 30 Sep 17 \| DIVISLAB	5%	₹59 Cr	88,814 ↑ 28,076
Ajanta Pharma Ltd (Healthcare) Equity, Since 31 Jul 17 \| AJANTPHARM	5%	₹57 Cr	195,295 ↓ -41,216
Gland Pharma Ltd (Healthcare) Equity, Since 30 Nov 20 \| GLAND	4%	₹48 Cr	215,251
Lupin Ltd (Healthcare) Equity, Since 28 Feb 25 \| LUPIN	4%	₹46 Cr	203,834 ↓ -6,166
Apollo Hospitals Enterprise Ltd (Healthcare) Equity, Since 30 Apr 21 \| APOLLOHOSP	4%	₹43 Cr	53,000
Dr Reddy's Laboratories Ltd (Healthcare) Equity, Since 28 Feb 18 \| DRREDDY	3%	₹38 Cr	290,000
Caplin Point Laboratories Ltd (Healthcare) Equity, Since 31 Dec 23 \| CAPLIPOINT	3%	₹37 Cr	185,000 ↑ 39,847
Alkem Laboratories Ltd (Healthcare) Equity, Since 31 May 21 \| ALKEM	3%	₹37 Cr	68,000
Fortis Healthcare Ltd (Healthcare) Equity, Since 31 Dec 20 \| FORTIS	3%	₹37 Cr	400,000

3. IDBI Small Cap Fund

The Investment objective of the Scheme is to provide investors with the opportunities for long-term capital appreciation by investing predominantly in Equity and Equity related instruments of Small Cap companies. However there can be no assurance that the investment objective under the Scheme will be realized.

Research Highlights for IDBI Small Cap Fund

Bottom quartile AUM (₹743 Cr).
Established history (9+ yrs).
Not Rated.
Risk profile: Moderately High.
5Y return: 17.01% (top quartile).
3Y return: 16.70% (bottom quartile).
1Y return: 9.50% (bottom quartile).
Alpha: 9.18 (upper mid).
Sharpe: 0.27 (bottom quartile).
Information ratio: -0.23 (bottom quartile).
Top sector: Industrials.
Top bond sector: Cash Equivalent.
Equity-heavy allocation (~98%).
Largest holding Garware Hi-Tech Films Ltd (~5.1%).

Below is the key information for IDBI Small Cap Fund

IDBI Small Cap Fund Growth
Launch Date	21 Jun 17
NAV (31 Jul 26)	₹33.3898 ↑ 0.27 (0.82 %)
Net Assets (Cr)	₹743 on 30 Jun 26
Category	Equity - Small Cap
AMC	IDBI Asset Management Limited
Rating	Not Rated
Risk	Moderately High
Expense Ratio	2.3
Sharpe Ratio	0.27
Information Ratio	-0.23
Alpha Ratio	9.18
Min Investment	5,000
Min SIP Investment	500
Exit Load	0-12 Months (1%),12 Months and above(NIL)

Growth of 10,000 investment over the years.

Date	Value
31 Jul 21	₹10,000
31 Jul 22	₹11,314
31 Jul 23	₹13,804
31 Jul 24	₹21,537
31 Jul 25	₹20,034

IDBI Small Cap Fund SIP Returns

Total investment amount is ₹300,000
expected amount after 5 Years is ₹470,047.
Net Profit of ₹170,047 Invest Now

Returns for IDBI Small Cap Fund

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 31 Jul 26

Duration	Returns
1 Month	-0.5%
3 Month	9.1%
6 Month	20%
1 Year	9.5%
3 Year	16.7%
5 Year	17%
10 Year
15 Year
Since launch	14.2%

Historical performance (Yearly) on absolute basis

Year	Returns
2024	-13.4%
2023	40%
2022	33.4%
2021	2.4%
2020	64.7%
2019	19%
2018	-4.4%
2017	-15%
2016
2015

Fund Manager information for IDBI Small Cap Fund

Name	Since	Tenure
Dikshit Mittal	24 Jul 25	0.93 Yr.
Mahesh Bendre	1 Jul 24	2 Yr.

Data below for IDBI Small Cap Fund as on 30 Jun 26

Equity Sector Allocation

Sector	Value
Industrials	27.58%
Basic Materials	16.22%
Consumer Cyclical	14.1%
Financial Services	11.08%
Consumer Defensive	9.75%
Health Care	6.95%
Technology	6.46%
Utility	2.92%
Real Estate	1.49%
Communication Services	0.98%

Asset Allocation

Asset Class	Value
Cash	2.48%
Equity	97.52%

Top Securities Holdings / Portfolio

Name	Holding	Value	Quantity
Garware Hi-Tech Films Ltd (Basic Materials) Equity, Since 30 Sep 25 \| 500655	5%	₹36 Cr	58,461 ↓ -1,326
Avalon Technologies Ltd (Technology) Equity, Since 31 Aug 23 \| AVALON	4%	₹26 Cr	167,845 ↓ -3,517
Navin Fluorine International Ltd (Basic Materials) Equity, Since 30 Sep 19 \| NAVINFLUOR	3%	₹21 Cr	29,286
Manorama Industries Ltd (Consumer Defensive) Equity, Since 31 Dec 24 \| 541974	3%	₹20 Cr	142,461 ↑ 22,179
KSH International Ltd (Industrials) Equity, Since 31 Dec 25 \| KSHINTL	3%	₹18 Cr	233,215 ↓ -16,165
Allied Blenders and Distillers Ltd (Consumer Defensive) Equity, Since 31 Jul 24 \| ABDL	3%	₹18 Cr	326,615
Schneider Electric Infrastructure Ltd (Industrials) Equity, Since 31 Aug 25 \| SCHNEIDER	3%	₹17 Cr	133,576
Arvind Fashions Ltd (Consumer Cyclical) Equity, Since 29 Feb 24 \| ARVINDFASN	2%	₹17 Cr	361,684 ↑ 53,437
Kirloskar Oil Engines Ltd (Industrials) Equity, Since 28 Feb 21 \| 533293	2%	₹15 Cr	78,792
Pricol Ltd (Consumer Cyclical) Equity, Since 30 Sep 25 \| PRICOLLTD	2%	₹13 Cr	237,103 ↑ 23,351

4. Aditya Birla Sun Life Manufacturing Equity Fund

The primary investment objective of the Schemes is to generate long-term capital appreciation to unit holders from a portfolio that is invested predominantly in equity and equity related securities of companies engaged in Manufacturing activity. The Scheme does not guarantee/indicate any returns. There can be no assurance that the schemes’ objectives will be achieved.

Research Highlights for Aditya Birla Sun Life Manufacturing Equity Fund

Bottom quartile AUM (₹1,229 Cr).
Established history (11+ yrs).
Not Rated.
Risk profile: High.
5Y return: 14.39% (bottom quartile).
3Y return: 19.72% (lower mid).
1Y return: 21.76% (top quartile).
Alpha: 0.00 (bottom quartile).
Sharpe: 0.54 (lower mid).
Information ratio: 0.00 (upper mid).
Higher exposure to Consumer Cyclical vs peer median.
Top bond sector: Cash Equivalent.
Equity-heavy allocation (~98%).
Largest holding Hindalco Industries Ltd (~5.6%).

Below is the key information for Aditya Birla Sun Life Manufacturing Equity Fund

Aditya Birla Sun Life Manufacturing Equity Fund Growth
Launch Date	31 Jan 15
NAV (31 Jul 26)	₹38.44 ↑ 0.31 (0.81 %)
Net Assets (Cr)	₹1,229 on 30 Jun 26
Category	Equity - Multi Cap
AMC	Birla Sun Life Asset Management Co Ltd
Rating	Not Rated
Risk	High
Expense Ratio	2.26
Sharpe Ratio	0.54
Information Ratio	0
Alpha Ratio	0
Min Investment	1,000
Min SIP Investment	1,000
Exit Load	0-365 Days (1%),365 Days and above(NIL)

Growth of 10,000 investment over the years.

Date	Value
31 Jul 21	₹10,000
31 Jul 22	₹9,679
31 Jul 23	₹11,411
31 Jul 24	₹16,928
31 Jul 25	₹16,083

Aditya Birla Sun Life Manufacturing Equity Fund SIP Returns

Total investment amount is ₹300,000
expected amount after 5 Years is ₹436,710.
Net Profit of ₹136,710 Invest Now

Returns for Aditya Birla Sun Life Manufacturing Equity Fund

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 31 Jul 26

Duration	Returns
1 Month	3.9%
3 Month	8.9%
6 Month	19.7%
1 Year	21.8%
3 Year	19.7%
5 Year	14.4%
10 Year
15 Year
Since launch	12.4%

Historical performance (Yearly) on absolute basis

Year	Returns
2024	3.5%
2023	25%
2022	32.5%
2021	-1.4%
2020	22.1%
2019	26.3%
2018	-4%
2017	-12.9%
2016	41.7%
2015	9.2%

Fund Manager information for Aditya Birla Sun Life Manufacturing Equity Fund

Name	Since	Tenure
Dhaval Joshi	13 May 26	0.13 Yr.

Data below for Aditya Birla Sun Life Manufacturing Equity Fund as on 30 Jun 26

Equity Sector Allocation

Sector	Value
Consumer Cyclical	27.93%
Industrials	26.34%
Basic Materials	19.65%
Health Care	11.14%
Consumer Defensive	4.47%
Energy	4.04%
Technology	1.61%
Utility	1.07%

Asset Allocation

Asset Class	Value
Cash	1.8%
Equity	98.2%

Top Securities Holdings / Portfolio

Name	Holding	Value	Quantity
Hindalco Industries Ltd (Basic Materials) Equity, Since 31 Mar 17 \| HINDALCO	6%	₹68 Cr	600,000
Cummins India Ltd (Industrials) Equity, Since 28 Feb 15 \| CUMMINSIND	4%	₹50 Cr	85,582
Reliance Industries Ltd (Energy) Equity, Since 31 Mar 19 \| RELIANCE	4%	₹48 Cr	366,616
Mahindra & Mahindra Ltd (Consumer Cyclical) Equity, Since 30 Nov 22 \| M&M	4%	₹44 Cr	144,570
Maruti Suzuki India Ltd (Consumer Cyclical) Equity, Since 28 Feb 15 \| MARUTI	3%	₹40 Cr	30,843
Tata Steel Ltd (Basic Materials) Equity, Since 30 Jun 16 \| TATASTEEL	3%	₹37 Cr	1,795,574
Sun Pharmaceuticals Industries Ltd (Healthcare) Equity, Since 30 Nov 22 \| SUNPHARMA	3%	₹34 Cr	190,238
Jindal Steel Ltd (Basic Materials) Equity, Since 31 Jul 24 \| JINDALSTEL	3%	₹31 Cr	256,435
Sansera Engineering Ltd (Consumer Cyclical) Equity, Since 31 Jan 24 \| SANSERA	2%	₹29 Cr	100,000
Samvardhana Motherson International Ltd (Consumer Cyclical) Equity, Since 30 Sep 24 \| MOTHERSON	2%	₹28 Cr	1,926,526

5. Motilal Oswal Focused 25 Fund

(Erstwhile Motilal Oswal MOSt Focused 25 Fund)

Research Highlights for Motilal Oswal Focused 25 Fund

Upper mid AUM (₹1,635 Cr).
Established history (13+ yrs).
Top rated.
Risk profile: Moderately High.
5Y return: 9.85% (bottom quartile).
3Y return: 11.56% (bottom quartile).
1Y return: 16.56% (upper mid).
Alpha: 12.39 (top quartile).
Sharpe: 0.35 (bottom quartile).
Information ratio: -0.21 (bottom quartile).
Higher exposure to Financial Services vs peer median.
Top bond sector: Cash Equivalent.
Equity-heavy allocation (~94%).
Largest holding Aditya Infotech Ltd (~4.9%).

Below is the key information for Motilal Oswal Focused 25 Fund

Motilal Oswal Focused 25 Fund Growth
Launch Date	7 May 13
NAV (31 Jul 26)	₹50.3259 ↑ 0.64 (1.29 %)
Net Assets (Cr)	₹1,635 on 30 Jun 26
Category	Equity - Focused
AMC	Motilal Oswal Asset Management Co. Ltd
Rating	☆☆☆
Risk	Moderately High
Expense Ratio	1.97
Sharpe Ratio	0.35
Information Ratio	-0.21
Alpha Ratio	12.39
Min Investment	5,000
Min SIP Investment	500
Exit Load	0-1 Years (1%),1 Years and above(NIL)

Growth of 10,000 investment over the years.

Date	Value
31 Jul 21	₹10,000
31 Jul 22	₹10,120
31 Jul 23	₹11,523
31 Jul 24	₹15,422
31 Jul 25	₹13,725

Motilal Oswal Focused 25 Fund SIP Returns

Total investment amount is ₹300,000
expected amount after 5 Years is ₹385,859.
Net Profit of ₹85,859 Invest Now

Returns for Motilal Oswal Focused 25 Fund

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 31 Jul 26

Duration	Returns
1 Month	3.4%
3 Month	12.4%
6 Month	18.6%
1 Year	16.6%
3 Year	11.6%
5 Year	9.9%
10 Year
15 Year
Since launch	13%

Historical performance (Yearly) on absolute basis

Year	Returns
2024	-1.7%
2023	13.6%
2022	18.8%
2021	2%
2020	14.6%
2019	17.3%
2018	17.1%
2017	-4.2%
2016	32.2%
2015	2.8%

Fund Manager information for Motilal Oswal Focused 25 Fund

Name	Since	Tenure
Varun Sharma	14 Aug 25	0.88 Yr.
Swapnil Mayekar	18 Nov 25	0.61 Yr.
Ankit Agarwal	5 Aug 25	0.9 Yr.
Rakesh Shetty	22 Nov 22	3.61 Yr.
Atul Mehra	1 Oct 24	1.75 Yr.

Data below for Motilal Oswal Focused 25 Fund as on 30 Jun 26

Equity Sector Allocation

Sector	Value
Financial Services	23.84%
Industrials	21.59%
Consumer Cyclical	17.2%
Technology	8.99%
Health Care	7.23%
Basic Materials	7.03%
Utility	3.18%
Communication Services	2.46%

Asset Allocation

Asset Class	Value
Cash	5.55%
Equity	94.45%

Top Securities Holdings / Portfolio

Name	Holding	Value	Quantity
Aditya Infotech Ltd (Industrials) Equity, Since 28 Feb 26 \| CPPLUS	5%	₹76 Cr	261,175
ICICI Prudential Asset Management Co Ltd (Financial Services) Equity, Since 31 Jan 26 \| ICICIAMC	4%	₹68 Cr	193,190 ↑ 8,826
Persistent Systems Ltd (Technology) Equity, Since 30 Apr 26 \| PERSISTENT	4%	₹66 Cr	127,008 ↑ 19,051
CG Power & Industrial Solutions Ltd (Industrials) Equity, Since 28 Feb 26 \| CGPOWER	4%	₹65 Cr	707,583 ↓ -71,782
AU Small Finance Bank Ltd (Financial Services) Equity, Since 31 Oct 25 \| AUBANK	4%	₹64 Cr	645,708 ↑ 40,286
Eternal Ltd (Consumer Cyclical) Equity, Since 31 Jan 26 \| ETERNAL	4%	₹63 Cr	2,529,956 ↑ 118,365
Apollo Hospitals Enterprise Ltd (Healthcare) Equity, Since 28 Feb 26 \| APOLLOHOSP	4%	₹62 Cr	75,565 ↑ 4,721
Gabriel India Ltd (Consumer Cyclical) Equity, Since 31 Aug 25 \| GABRIEL	4%	₹59 Cr	536,227
Aditya Vision Ltd (Consumer Cyclical) Equity, Since 30 Sep 25 \| 540205	4%	₹55 Cr	1,020,017
ABB India Ltd (Industrials) Equity, Since 31 May 26 \| ABB	3%	₹54 Cr	74,566 ↑ 74,566

म्यूचुअल फंड में ऑनलाइन निवेश कैसे करें?

Fincash.com पर आजीवन मुफ्त निवेश खाता खोलें।

अपना पंजीकरण और केवाईसी प्रक्रिया पूरी करें

Upload Documents (PAN, Aadhaar, etc.). और, आप निवेश करने के लिए तैयार हैं!

शुरू हो जाओ

Disclaimer:
यहां प्रदान की गई जानकारी सटीक है, यह सुनिश्चित करने के लिए सभी प्रयास किए गए हैं। हालांकि, डेटा की शुद्धता के संबंध में कोई गारंटी नहीं दी जाती है। कृपया कोई भी निवेश करने से पहले योजना सूचना दस्तावेज के साथ सत्यापित करें।